CA
NZ
UK
AU
IND
US
● Third-quarter guidance from July called for adjusted EPS of $2.14 to $2.24.
● Skyrizi and Rinvoq together brought in nearly $8.5 billion, roughly half of revenue.
● The filing received Priority Review under theAccelerated Approvalpathway in July.
● Bambusa Therapeutics priced mid-range at $16 and upsized its deal the same night.
● Aspen Neuroscience and OPay priced at the low end, while Bambusa landed higher.
● The 2026 revenue outlook was raised to $15.9 billion to $16.125 billion.
● 2026 revenue guidance is now $5.20 billion to $5.25 billion, with a higher midpoint.
● Health care was the best-performing S&P 500 sector during the regular session.
● GrossMarginnarrowed and 2027 guidance will not come until February.
● 2026 revenue guidance was raised to $49.75 billion to $50.25 billion.
Please wait processing your request...